Who are Recombinant Staphylokinase's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Activase, Trasylol, Cyklokapron, Amicar, Tranexamic Acid (IV), IV TXA.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/recombinant-staphylokinase.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Recombinant Staphylokinase — Competitive Intelligence Brief

Recombinant Staphylokinase (Recombinant Staphylokinase) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fibrinolytic agent / Thrombolytic. Area: Cardiovascular.

marketed Fibrinolytic agent / Thrombolytic Plasminogen Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Recombinant Staphylokinase (Recombinant Staphylokinase) — The First Affiliated Hospital with Nanjing Medical University. Recombinant staphylokinase is a fibrinolytic enzyme that directly activates plasminogen to plasmin, dissolving blood clots.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Recombinant Staphylokinase TARGET	Recombinant Staphylokinase	The First Affiliated Hospital with Nanjing Medical University	marketed	Fibrinolytic agent / Thrombolytic	Plasminogen
Activase	ALTEPLASE	Roche	marketed		Plasminogen	1996-01-01
Trasylol	APROTININ	Bayer	marketed	Antifibrinolytic Agent	Plasminogen	1993-01-01
Cyklokapron	TRANEXAMIC ACID	Exela Pharma	marketed	Antifibrinolytic Agent [EPC]	Plasminogen	1986-01-01
Amicar	AMINOCAPROIC ACID	Epic Pharma Llc	marketed	Antifibrinolytic Agent [EPC]	Plasminogen	1964-01-01
Tranexamic Acid (IV)	Tranexamic Acid (IV)	Samsung Medical Center	marketed	Antifibrinolytic agent	Plasminogen / Plasmin
IV TXA	IV TXA	Massachusetts General Hospital	marketed	Antifibrinolytic agent	Plasminogen / Plasmin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fibrinolytic agent / Thrombolytic class)

All India Institute of Medical Sciences · 1 drug in this class
Angde Biotech Pharmaceutical Co., Ltd. · 1 drug in this class
Beijing Chao Yang Hospital · 1 drug in this class
Beijing Tiantan Hospital · 1 drug in this class
Life Recovery Systems · 1 drug in this class
Tasly Biopharmaceuticals Co., Ltd. · 1 drug in this class
The First Affiliated Hospital with Nanjing Medical University · 1 drug in this class
Thrombolex, Inc. · 1 drug in this class
Tianjin Huanhu Hospital · 1 drug in this class
University of North Carolina, Chapel Hill · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Recombinant Staphylokinase — Competitive Intelligence Brief. https://druglandscape.com/ci/recombinant-staphylokinase. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab